BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• BRAF mutations, particularly BRAF V600E, are key drivers in various cancers, including melanoma, colorectal, and non-small-cell lung cancer.
• Targeted therapies inhibiting BRAF and MEK have shown efficacy, especially in melanoma, improving patient survival rates.

Purpose of the Study:

• To review the role of BRAF mutations in cancer and the challenges associated with targeted therapies.
• To explore emerging strategies, including immunotherapy combinations, to overcome treatment resistance.
• To emphasize the importance of tumor origin and microenvironment in therapeutic response.

Main Methods:

• Literature review of BRAF mutations in cancer.
• Analysis of targeted therapy mechanisms and resistance pathways.
• Exploration of combination strategies and future research directions.

Main Results:

• BRAF V600E is a significant therapeutic target, with inhibitors improving outcomes in melanoma.
• Resistance to BRAF/MEK inhibitors arises from secondary mutations, alternative pathway activation (PI3K/AKT), and tumor microenvironment changes.
• Metastatic colorectal cancer with BRAF mutations shows poor prognosis and chemoresistance.

Conclusions:

• BRAF inhibitors offer benefits but face resistance challenges.
• Combining BRAF inhibitors with immunotherapy is a promising strategy to enhance treatment efficacy.
• Understanding cancer-specific biology, including tissue of origin and tumor microenvironment, is crucial for optimizing targeted therapies.